Glaucoma is the leading cause of irreversible blindness, primarily characterized by retinal ganglion cell (RGC) loss and optic nerve damage due to abnormal alterations in intraocular pressure (IOP). While in vivo models provide valuable insights into its pathophysiology, they face limitations in controlling biomechanical parameters and long-term IOP monitoring. In vitro models offer greater experimental control but often lack the complexity of the ocular microenvironment, limiting their physiological relevance. To better understand RGC degeneration from a biomechanical perspective, advancements are needed to improve these models, including precise pressure manipulation and more realistic cell culture conditions. This review summarizes current in vitro approaches for studying pressure-induced RGC degeneration and explores the potential of microfluidic technologies to enhance model fidelity. Incorporating microfluidic technologies holds promise for creating more physiologically relevant models, potentially advancing our understanding of IOP-related RGC degeneration from biomechanical perspectives.
The measurement of cardiac troponin I (cTnI) is of vital importance for the early diagnosis of acute myocardial infarction. In this study, an enhanced electrochemiluminescent immunoassay for the highly sensitive and precise determination of cTnI was reported. A biomimetic chip with nepenthes peristome surface microstructures to achieve single-layer microbead arrays and integrated microelectrode arrays (MEAs) for ECL detection was microfabricated. Ru@SiO2 nanoparticles were prepared as signal amplificators labeling immunomagnetic beads. Dendrimer-encapsulated platinum nanoparticles (Pt DENs) were electrochemically modified on ITO MEAs. The resulting Pt DEN-modified ITO MEAs preserved good optical transparency and exhibited an approximately 20-fold ECL signal amplification compared to that obtained from bare ITO. The method made full use of the biomimetic chip with Pt DENs to develop single-layer immunomagnetic bead arrays with increasingly catalyzed electrochemical oxidation of the [Ru(bpy)3]2+–TPA system. Consequently, a limit of detection calculated as 0.38 pg/mL (S/N = 3) was obtained with excellent selectivity, demonstrating significant potential for the detection of cTnI in clinical diagnostics.